Pulmonary Vascular Disease News

SAN DIEGO — During 2019 and 2020, patients with pulmonary arterial hypertension lost around 8% of available workdays, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Between 2017 and 2023, the highest rate of pulmonary embolism admissions was found in 2021 during the COVID-19 pandemic, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Measures of pulmonary vascular disease and right ventricular function improved with longer lifetime menses in pulmonary hypertension, according to research presented at the American Thoracic Society International Conference.

Two catheter-directed thrombectomy devices demonstrated efficacy and safety in the treatment of acute intermediate-risk pulmonary embolism, speakers reported.

Use of advanced thrombolysis in the U.S. remains low and is prone to disparate use among women and Black patients presenting with pulmonary embolism, a speaker reported.

Penumbra announced the FDA clearance and launch of its next-generation computer-assisted vacuum thrombectomy system to remove venous thrombus and treat pulmonary emboli.

The 2022 European Society of Cardiology risk assessment tool, when applied at baseline and follow-up, can accurately predict survival in patients with systemic sclerosis-associated pulmonary arterial hypertension, according to data.

Among adults with pulmonary arterial hypertension, patient characteristics, mortality and treatment varied across four U.S. census regions, according to results published in Annals of the American Thoracic Society.

The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.